Indication
Triple-Negative Breast Cancer
242 clinical trials
325 products
45 drugs
Clinical trial
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin LymphomaStatus: Terminated, Estimated PCD: 2023-02-13
Product
NIR178Product
PDR001Clinical trial
A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult Patients With Advanced Solid Tumors and Triple Negative Breast CancersStatus: Active (not recruiting), Estimated PCD: 2023-01-31
Clinical trial
A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid TumorStatus: Recruiting, Estimated PCD: 2024-09-01
Product
AtezolizumabClinical trial
A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid MalignanciesStatus: Recruiting, Estimated PCD: 2025-08-01
Product
FludarabineProduct
TebotelimabClinical trial
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic NeoplasmsStatus: Completed, Estimated PCD: 2023-02-08
Clinical trial
An Open-Label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Tislelizumab in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Product
CRX100Product
CyclophosphamideClinical trial
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced MalignanciesStatus: Terminated, Estimated PCD: 2023-12-01
Clinical trial
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-11-14
Product
LGK974Clinical trial
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt LigandsStatus: Active (not recruiting), Estimated PCD: 2021-06-14
Clinical trial
A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.Status: Recruiting, Estimated PCD: 2025-04-30
Product
BT-001Product
FAZ053Clinical trial
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients With Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2025-10-01
Product
PembrolizumabProduct
AO-252Product
CTX-8371Clinical trial
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-10-28
Product
margetuximabProduct
FruquintinibProduct
TislelizumabClinical trial
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and LymphomasStatus: Recruiting, Estimated PCD: 2026-04-30
Product
BDC-3042Product
ONM-501Product
CemiplimabClinical trial
A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-01
Product
TT-00420Clinical trial
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-06-30
Product
Nab-PaclitaxelProduct
MDNA11Product
XMT-1660Product
SEA-TGTProduct
sasanlimabProduct
Brentuximab vedotinClinical trial
A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid MalignanciesStatus: Terminated, Estimated PCD: 2023-11-01
Product
CamrelizumabClinical trial
A Multicentre, Randomized, Double-blind, Parallel-controlled Phase Ⅲ Study to Evaluate Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Patients With Early or Locally Advanced Triple Negative Breast Cancer (TNBC).Status: Completed, Estimated PCD: 2023-09-14
Clinical trial
A Phase 1b/2, Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacodynamics and Antitumor Activity of GX-I7 in Combination With Pembrolizumab in Subjects With Refractory or Relapsed (R/R) TNBCStatus: Completed, Estimated PCD: 2023-05-11
Product
placebo+chemotherapyProduct
MEM-288Product
NivolumabProduct
GX-I7Product
ATRC-101Product
NM21-1480Clinical trial
Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic SettingStatus: Active (not recruiting), Estimated PCD: 2023-11-20
Clinical trial
A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2024-02-06
Product
TrilaciclibProduct
Sacituzumab GovitecanClinical trial
Phase I Study of MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2025-11-01
Product
TC-510Clinical trial
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing CancerStatus: Active (not recruiting), Estimated PCD: 2028-10-30
Product
AL101Clinical trial
A Phase 2, Multi-center, Open-label, Single Arm Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast CancerStatus: Terminated, Estimated PCD: 2022-03-23
Clinical trial
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Product
GemcitabineClinical trial
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple MyelomaStatus: Terminated, Estimated PCD: 2022-12-02
Product
CART-TnMUC1Product
PlaceboProduct
CarboplatinProduct
PF-06873600Clinical trial
PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPYStatus: Active (not recruiting), Estimated PCD: 2023-04-05
Product
Endocrine TherapyProduct
LYL797Clinical trial
A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2025-03-01
Product
PBA-0405Clinical trial
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0405 in Patients With Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2025-03-01
Product
PamiparibClinical trial
An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2020-08-24
Product
VobramitamabClinical trial
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-03-18
Product
Brentuximab VedotinClinical trial
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-06-01
Product
NUV-868Clinical trial
Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2026-10-01
Product
Naptumomab estafenatoxProduct
ObinutuzumabClinical trial
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Product
SO-C101Clinical trial
A Randomized Non-comparative Open-label Phase 1b/2 Study of Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. "TRIFOUR Study"Status: Recruiting, Estimated PCD: 2024-08-01
Product
NadunolimabProduct
VLS-1488Clinical trial
A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced CancerStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
An Open-label Phase 1b/2a Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-11-05
Product
NT-I7Product
NM32-2668Clinical trial
A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With Selected Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-12-31
Product
COM701Clinical trial
A Phase 1a/1b Study of COM701 as Monotherapy and In Combination With an Anti-PD-1 Antibody in Subjects With Advanced Solid Tumors.Status: Active (not recruiting), Estimated PCD: 2024-02-29
Product
COM701 with OpdivoProduct
JK08Clinical trial
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients With Unresectable Locally Advanced or Metastatic CancerStatus: Recruiting, Estimated PCD: 2025-10-17
Clinical trial
A PhI Dose Escalation Study of LAE005+Afuresertib+Nab_Paclitaxel in Advanced Solid Tumors and PhII Study to Evaluate the Safety and Efficacy of LAE005+Afur+Nab_Paclitaxel or LAE005/Afur+Nab-Paclitaxel in Locally Advanced or mTNBCStatus: Completed, Estimated PCD: 2023-12-11
Product
LAE005Product
vidutolimodProduct
cemiplimabClinical trial
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic CancerStatus: , Estimated PCD: 2027-07-29
Product
NKT3447Clinical trial
A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2024-02-22
Product
INCB106385Product
INCMGA00012Product
XL102Clinical trial
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
AbirateroneClinical trial
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-01
Product
Autogene cevumeranClinical trial
A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase IIA Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid With Adjuvant Chemotherapy in Patients With Triple Negative Breast Cancer (TNBC) After SurgeryStatus: Not yet recruiting, Estimated PCD: 2025-04-30
Clinical trial
A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic TumorsStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Product
FulvestrantProduct
BLEX 404Product
pembrolizumabProduct
PY314Clinical trial
A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-08-31
Product
PY314 + PembrolizumabProduct
ImmunotherapyClinical trial
ARGONAUT: Development and Analysis of a Blood and Stool Sample Bank for Cancer Patients, Enabling the Systematic Study of the Effect of Gut Microbiomes on Response to TreatmentStatus: Recruiting, Estimated PCD: 2024-12-31
Product
PrednisoneProduct
ChemotherapyClinical trial
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)Status: Recruiting, Estimated PCD: 2025-12-30
Product
PD-1 inhibitorProduct
CAB-ROR2-ADCClinical trial
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-08-05
Product
KY1044Product
KY1044 and AtezolizumabProduct
PRO1107Clinical trial
A Muti-center, Open-label, Randomized, Phase III Study of Camrelizumab Plus Treatment of Physician Choice Versus Treatment of Physician Choice for Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Systemic Chemotherapy Regimens for Advanced/Metastatic SettingStatus: Terminated, Estimated PCD: 2022-01-17
Clinical trial
A Phase 1/2 Study of PRO1107 in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-02-01
Clinical trial
Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours (TROPION-PanTumor02)Status: Active (not recruiting), Estimated PCD: 2023-11-07
Product
Datopotamab DeruxtecanClinical trial
A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-09-12
Product
DKY709Clinical trial
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With High Risk, Early Stage Globo H-Positive Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-12-30
Product
OlaparibProduct
EnzalutamideProduct
PaclitaxelProduct
CB-839Clinical trial
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African AncestryStatus: Completed, Estimated PCD: 2019-11-25
Clinical trial
A Global, Multicenter, Three Arms, Open-label Randomized Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension Compared to Taxotere® (Docetaxel Injection Concentrate) in Triple-negative Breast Cancer Patients With Locally Advanced or Metastatic Breast Cancer After Failure to Prior ChemotherapyStatus: Recruiting, Estimated PCD: 2024-05-31
Product
CYT-0851Clinical trial
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-30
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
AcasunlimabClinical trial
A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients With Early-Stage Triple Negative Breast Cancer (TNBC)Status: Completed, Estimated PCD: 2022-10-31
Product
CylophosphamideProduct
DoxorubicinClinical trial
A Phase 2 Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Pembrolizumab +/- Chemotherapy in Patients With Inoperable Locally Advanced/Metastatic Triple-Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Product
Nab PaclitaxelProduct
Gemcitabine + CarboplatinProduct
Tavokinogene TelseplasmidProduct
RAPA-201Product
OciperlimabClinical trial
AdvanTIG-211: A Randomized, Double-blind, Placebo-controlled, Phase II Study Evaluating the Efficacy and Safety of Ociperlimab (WCD118) Combined With Tislelizumab (VDT482) Plus Chemotherapy Versus Placebo Combined With Pembrolizumab Plus Chemotherapy as First-line Therapy for Participants With Advanced Triple Negative Breast Cancer (TNBC)Status: Withdrawn, Estimated PCD: 2029-07-17
Product
Nab-paclitaxelClinical trial
Phase I/II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid TumorsStatus: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed TumorsStatus: Completed, Estimated PCD: 2021-06-30
Product
EDP1503Clinical trial
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)Status: Completed, Estimated PCD: 2023-02-16
Product
CAN04Clinical trial
An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant TumorsStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Product
navicixizumab+paclitaxelProduct
navicixizumab+irinotecanClinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid TumorsStatus: Terminated, Estimated PCD: 2023-05-31
Product
XmAb®22841Clinical trial
A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-05-31
Product
CisplatinProduct
PemetrexedProduct
SKB264Product
ONCR-177Product
ST316Clinical trial
A Randomized, Controlled, Open-label, Multi-center Phase III Clinical Trial of SKB264 for Injection Versus Investigator Selected Regimens in Patients With Unresectable Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer Who Have Failed Second-line or Above Prior Standard of CareStatus: Active (not recruiting), Estimated PCD: 2023-10-31
Clinical trial
A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-04-15
Product
LenvatinibClinical trial
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)Status: Active (not recruiting), Estimated PCD: 2024-12-20
Product
NavicixizumabClinical trial
A Phase 1/2 Study of RTX-224 for the Treatment of Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2022-11-30
Clinical trial
A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-08-01
Product
JAB-2485Product
TaxotereClinical trial
A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2023-08-14
Clinical trial
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian CancerStatus: Completed, Estimated PCD: 2018-05-14
Product
Modi-1/Modi-1vClinical trial
A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients With Breast, Head and Neck, Ovarian, or Renal CancerStatus: Recruiting, Estimated PCD: 2026-04-04
Product
niraparibProduct
IT-pIL12-EPClinical trial
Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2018-07-01
Clinical trial
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2022-12-13
Clinical trial
A Phase Ib/IIa, Multicenter, Open-label Study of ILB2109 and Toripalimab in Patients With Advanced Solid MalignanciesStatus: Not yet recruiting, Estimated PCD: 2026-01-25
Product
ToripalimabClinical trial
Phase Ib/ll Clinical Study to Evaluate Safety and Dosing of Humanised Monoclonal Antibody CA9hu-1 to Human Carbonic Anhydrase IX in Patients With Advanced Solid TumoursStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Product
ILB-2109Product
RTX-224Product
CA9hu-1Clinical trial
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) With or Without Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor MalignanciesStatus: Terminated, Estimated PCD: 2022-05-09
Clinical trial
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)Status: Completed, Estimated PCD: 2022-02-22
Product
HDM201Product
LCL161Product
EverolimusProduct
PanobinostatProduct
QBM076Product
NKTR-262Product
BT5528Clinical trial
A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor MalignanciesStatus: Completed, Estimated PCD: 2022-04-28
Clinical trial
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 ExpressionStatus: Recruiting, Estimated PCD: 2023-12-31
Product
bempegaldesleukinProduct
nivolumabClinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1029 in Patients With Malignant Solid TumorsStatus: Terminated, Estimated PCD: 2021-10-12
Product
GEN1029Clinical trial
FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and MesotheliomaStatus: Recruiting, Estimated PCD: 2026-06-01
Product
PMD-026Product
EtrumadenantClinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic MalignanciesStatus: Completed, Estimated PCD: 2021-07-01
Clinical trial
A Multicentre, Open-parallel, Randomized, Controlled Phase Ⅲ Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer.Status: Terminated, Estimated PCD: 2023-04-14
Product
CarelizumabProduct
ApatinibProduct
cabozantinibProduct
atezolizumabProduct
NBE-002Product
NI-1801Clinical trial
A First-in-Human, Phase 1/2 Study of NBE-002, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-08-14
Clinical trial
A Phase 1, Open-label, Dose Finding Study of NI-1801, a Bispecific Mesothelin x CD47 Engaging Antibody, in Patients With Mesothelin Expressing Solid CancersStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2015-07-01
Clinical trial
Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-PanTumor01)Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid TumoursStatus: Recruiting, Estimated PCD: 2024-01-01
Product
AMT-151Clinical trial
A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid TumorsStatus: Completed, Estimated PCD: 2023-02-08
Clinical trial
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERSStatus: Completed, Estimated PCD: 2022-12-28
Product
CPI-006Product
CPI-006 + PembrolizumabProduct
HMBD-002Clinical trial
A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid MalignanciesStatus: Recruiting, Estimated PCD: 2024-10-01
Product
ABBV-927Clinical trial
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-11-12
Clinical trial
A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic CancersStatus: Recruiting, Estimated PCD: 2026-03-31
Product
OC-001Clinical trial
A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)Status: Recruiting, Estimated PCD: 2030-12-01
Product
Standard TherapyClinical trial
A Randomized, Open Label, Parallel Controlled, Multicenter Phase II Clinical Study of Carelizumab Combined With TCb (Docetaxel+Carboplatin) Versus TCb Neoadjuvant Therapy for Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Product
Carrelizumab + TCb regimenProduct
TCbProduct
Pertuzumab + TrastuzumabProduct
GanetespibProduct
ABT-888Product
NeratinibClinical trial
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic CancerStatus: Recruiting, Estimated PCD: 2025-09-30
Product
LY2880070Drug
GemcitabineProduct
SGN-LIV1AProduct
Durvalumab + OlaparibProduct
SD-101 + PembrolizumabClinical trial
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)Status: Recruiting, Estimated PCD: 2024-09-01
Product
Nab paclitaxelDrug
AN0025Drug
EpirubicinDrug
cyclophosphamideProduct
FluzoparibDrug
HER2 ADCClinical trial
Neoadjuvant and Adjuvant Olaparib Plus Pembrolizumab Following Platinum Based Chemotherapy Plus Pembrolizumab for Germline BRCA Mutated Triple Negative Breast Cancer (WJOG14020B/OPERETTA)Status: Recruiting, Estimated PCD: 2025-09-30
Drug
TiragolumabClinical trial
P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-06-01
Product
ARX788 + CemiplimabProduct
VV1 + CemiplimabClinical trial
A Phase II Trial of Atezolizumab Plus CArboplatin Plus Nab-paclitaxel as First-line Therapy in Metastatic Triple-negative PD-L1 Positive Breast Cancer Patients - the GIM25-CAPT TrialStatus: Active (not recruiting), Estimated PCD: 2024-07-03
Clinical trial
A Phase II Trial of Carboplatin +/- Tocilizumab as Initial Therapy for Metastatic Triple Negative and ER-low Breast CancersStatus: Recruiting, Estimated PCD: 2026-12-01
Drug
TocilizumabClinical trial
A Multicenter, Randomized, Controlled, Open Label Clinical Study on the Treatment of Recurrent or Metastatic Triple Negative Breast Cancer With Cadonilimab Combined With Eribulin Versus Eribulin AloneStatus: Not yet recruiting, Estimated PCD: 2025-12-30
Drug
CadonilimabClinical trial
Randomized, Phase II Trial to Evaluate the Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy Compared to Capecitabine Monotherapy for TNBC With Residual Invasive Cancer After Neoadjuvant Chemotherapy.Status: Active (not recruiting), Estimated PCD: 2024-01-31
Drug
AtezolizumabProduct
CapecitabineClinical trial
Efficacy of Intralesional IL-2 for Resectable Triple Negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2024-04-01
Product
Human Interleukin-2 (IL-2)Clinical trial
A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care TherapyStatus: Terminated, Estimated PCD: 2022-11-21
Product
DurvalumabProduct
Neoantigen DNA vaccineClinical trial
Contrast Enhanced Digital Mammography for Predicting Pathologic Complete Response After Neoadjuvant ChemotherapyStatus: Recruiting, Estimated PCD: 2026-07-31
Product
Omnipaque 350mgI/mLClinical trial
Phase II Study of Docetaxel Chemotherapy With Pembrolizumab and Interleukin-12 Gene Therapy in Patients With Anthracycline- Refractory Triple Negative Breast Cancer (INTEGRAL)Status: , Estimated PCD: 2024-06-01
Drug
DocetaxelProduct
IL-12Clinical trial
Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337Status: Active (not recruiting), Estimated PCD: 2024-07-01
Product
GedatolisibProduct
TalazoparibClinical trial
A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2019-08-21
Clinical trial
A Phase II Single Center Two Cohorts Trial of LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast CancerStatus: Recruiting, Estimated PCD: 2026-04-01
Product
LM-108Drug
PD-1 antibodyProduct
EribulinClinical trial
A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Investigator-initiated Phase II Study of Pembrolizumab Immunological Response EvaluationStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
An Umbrella Trial Based on Molecular Pathway for Patients With Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer (FUTURE SUPER)Status: Active (not recruiting), Estimated PCD: 2023-05-31
Product
PyrotinibProduct
Everolimus + Nab-PaclitaxelProduct
nab-paclitaxelProduct
C1: PD-1Product
D1: VEGFR and nab-paclitaxelProduct
D2: nab-paclitaxelClinical trial
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early Triple-negative Breast Cancer (TNBC). An Open-label Randomized Two-cohort Phase 2 Clinical Trial. INVINCIBLE-4-SAKKStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Product
INT230-6Clinical trial
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBCStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid StructuresStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Product
EzabenlimabClinical trial
Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Product
CrizotinibClinical trial
Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor TypesStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Product
IpilimumabClinical trial
A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Pembrolizumab in HLA-A2+ Patients With Metastatic Triple Negative Breast Cancer (TNBC)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Product
PVX-410Clinical trial
A Multicenter, Open-Label, Non-Comparative, Three-Arm, Phase IIa Trial of Ipatasertib (GDC-0068) in Combination With Non-Taxane Chemotherapy Agents for Taxane-Pretreated Unresectable Locally Advanced or Metastatic TNBC PatientsStatus: Completed, Estimated PCD: 2023-11-10
Product
IpatasertibClinical trial
A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast CancerStatus: Active (not recruiting), Estimated PCD: 2019-05-13
Product
IndomethacinProduct
OmeprazoleClinical trial
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2023-03-20
Drug
T-VECProduct
CabiralizumabClinical trial
A Combined Phase i/II Efficacy Study of a Carbohydrate Mimotope-based Vaccine With MONTANIDE™ ISA 51 VG STERILE Combined With Neoadjuvant Chemotherapy in Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2023-01-09
Product
P10s-PADREClinical trial
Neoadjuvant Olaparib and Durvalumab for Patients With BRCA-associated Triple Negative Breast CancerStatus: Withdrawn, Estimated PCD: 2028-09-06
Drug
olaparibClinical trial
PAveMenT: Phase Ib Study of Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-07-31
Product
PalbociclibClinical trial
A Phase IB/II Study of Durvalumab (MEDI4736) Combined With Dose-dense EC in a Neoadjuvant Setting for Patients With Locally Advanced Luminal B HER2(-) or Triple Negative Breast Cancers.Status: Completed, Estimated PCD: 2022-11-21
Clinical trial
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-07
Product
XB002Product
NKTR-214 + NivolumabProduct
AG-01Clinical trial
Phase 1/1b Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 in Patients With Metastatic Breast Cancer With Expansion in Metastatic Triple Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
IPI-549Product
E7449Product
Steroid Containing MouthwashClinical trial
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-07-01
Product
TJ004309Product
ABBV-368Product
ABBV-181Product
TH1902Drug
LHRH agonistClinical trial
ISIdE: Open Label, Multicentric, Single-arm Phase IIIB Trial to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Triple Negative Metastatic Breast Cancer Patients With a Biomarker AnalysisStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-08-26
Product
LY4101174Product
AMG 386Product
AMG 479Product
MK-2206Product
AMG 386 + TrastuzumabProduct
T-DM1 + PertuzumabClinical trial
Phase II Study of Pembrolizumab and Ablative Radiotherapy With or Without Olaparib in Metastatic Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancers : Initial Test Cohorts of a Platform Trial to Sequentially Investigate Immunotherapy Combinations for the Augmentation of Immune ResponsesStatus: Recruiting, Estimated PCD: 2025-01-01
Product
PLX3397Product
Talazoparib + IrinotecanProduct
Patritumab and TrastuzumabClinical trial
A Randomized, Open Label, Multicenter Phase III Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)Status: Recruiting, Estimated PCD: 2025-08-30
Product
LetrozoleClinical trial
A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)Status: Recruiting, Estimated PCD: 2029-01-31
Drug
InavolisibProduct
SYD985Clinical trial
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2027-09-30
Product
NM1FDrug
AmcenestrantProduct
Amcenestrant + AbemaciclibProduct
Amcenestrant + LetrozoleDrug
ARX788Clinical trial
A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-11-30
Product
Paclitaxel + CarboplatinProduct
Datopotamab deruxtecanProduct
ZanidatamabDrug
LasofoxifeneProduct
Z-endoxifenClinical trial
A Phase II Study of NirAparib, Dostarlimab and Radiotherapy in Metastatic, PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR)Status: Recruiting, Estimated PCD: 2025-04-01
Product
NiraparibProduct
DostarlimabProduct
ARV-471Product
ARV-471 + LetrozoleClinical trial
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR(+) Triple Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Multicenter, Randomized, Phase II Study of Neoadjuvant Chemotherapy Associated or Not With Zoledronate and Atorvastatin in Triple Negative Breast Cancers - YAPPETIZER StudyStatus: Completed, Estimated PCD: 2021-06-17
Product
ZoledronateProduct
AtorvastatinProduct
Standard neoadjuvant chtClinical trial
Comparing TP (Docetaxel + Cisplatin) and TAC (Docetaxel + Doxorubicin + Cyclophosphamide) in Neoadjuvant Therapy for Operable Triple Negative Breast Cancer, A Multicenter, Randomized, Phase II Clinical TrialStatus: Completed, Estimated PCD: 2022-11-26
Product
Docetaxel + CisplatinClinical trial
Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate) for Patients With HER2-low Locally Advanced Unresectable / Metastatic Breast CancerStatus: Not yet recruiting, Estimated PCD: 2027-09-30
Product
AldesleukinClinical trial
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) BiomarkerStatus: Completed, Estimated PCD: 2019-01-01
Clinical trial
Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan With Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer With Brain MetastasesStatus: Not yet recruiting, Estimated PCD: 2027-02-01
Product
ZimberelimabClinical trial
NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan Versus Sacituzumab Govitecan+Pembrolizumab in Low-risk, Triple-negative Early Breast Cancer (ADAPT-TN-III)Status: Not yet recruiting, Estimated PCD: 2029-09-01
Drug
CisplatinDrug
fludarabineClinical trial
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic Chemotherapy of Vinorelbine, Cyclophosphamide and Capecitabine (VEX) Regime in Advanced Triple-negative Breast Cancer: a Multicenter, Randomized, Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2025-01-19
Drug
AdebrelimabProduct
VinorelbineClinical trial
TreAtment Response and Omic-Markers in Triple-Negative Breast CAncer Patients Receiving Standard of Care Chemotherapy (TARMAC)Status: Not yet recruiting, Estimated PCD: 2029-06-01
Clinical trial
Study of Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors and Containing the Inducible Caspase 9 Safety Switch in Subjects With Triple Negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-05-01
Product
iC9-CAR.B7-H3Clinical trial
A Single-center, Randomized, Open-label, Phase III Study Comparing PD-1 Combined With Anthracycline/Taxane-based Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast CancerStatus: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast CancerStatus: Completed, Estimated PCD: 2024-01-30
Clinical trial
An Open-label Phase II Trial Evaluating the Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in Early-stage Triple-negative Breast Cancer（NeoSACT）Status: Recruiting, Estimated PCD: 2023-08-31
Product
SintilimabDrug
AnlotinibClinical trial
Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer: A Phase II TrialStatus: Recruiting, Estimated PCD: 2026-08-15
Product
Tumor samples analysisClinical trial
A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast CancerStatus: Recruiting, Estimated PCD: 2027-08-01
Drug
TrastuzumabProduct
PertuzumabDrug
ASTX727Clinical trial
A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast CancerStatus: Terminated, Estimated PCD: 2022-02-18
Clinical trial
A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)Status: Active (not recruiting), Estimated PCD: 2025-12-30
Clinical trial
Phase II Open-label, Single-arm Trial of Neoadjuvant Pembrolizumab With Carboplatin and Paclitaxel in Triple-negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2027-04-01
Clinical trial
Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) OligoprogressionStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Product
Standard of careClinical trial
A Phase II Study of Sitravatinib in Metastatic, Pre-treated, Triple Negative Breast CancerStatus: Terminated, Estimated PCD: 2021-09-22
Drug
SitravatinibClinical trial
IIT2021-01-Shiao-CSF1Ri: Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationStatus: Recruiting, Estimated PCD: 2025-12-01
Product
AxatilimabClinical trial
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical StudyStatus: Recruiting, Estimated PCD: 2025-10-30
Product
UtideloneProduct
AvelumabClinical trial
A Phase 2b Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast CancerStatus: Terminated, Estimated PCD: 2024-03-07
Drug
ZEN003694Clinical trial
Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing: A-TRAINStatus: Recruiting, Estimated PCD: 2024-12-31
Product
NGS analysis of ctDNAClinical trial
A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2024-02-20
Drug
Nab-PaclitaxelClinical trial
Phase II Trial Evaluating the Efficacy and Safety of Neoadjuvant Neratinib and Chemotherapy in Early Stage Triple-Negative Breast Cancer Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis (FACT-2)Status: Active (not recruiting), Estimated PCD: 2024-12-15
Clinical trial
Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer Based on High-Resolution Dynamic Immune Signature AnalysisStatus: Not yet recruiting, Estimated PCD: 2026-02-28
Clinical trial
A Pilot Study of Neoadjuvant Response-Adapted Chemotherapy With Pembrolizumab in Patients With Stage 2 and 3 Triple Negative Breast Cancer to Determine Early PET and Biomarker DynamicsStatus: Recruiting, Estimated PCD: 2029-06-01
Drug
mFOLFOX6Drug
doxorubicinDrug
UTD1Clinical trial
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Phase II Study of Neoadjuvant QL1706 Plus Chemotherapy in Participants With High-Risk TNBC Early-Stage Breast Cancer (QUEEN-Dream)Status: Not yet recruiting, Estimated PCD: 2025-11-07
Clinical trial
PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform TrialStatus: Recruiting, Estimated PCD: 2026-12-30
Drug
TucatinibClinical trial
A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Product
MEDI9447Clinical trial
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-12-31
Product
VisiumClinical trial
A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024Status: Recruiting, Estimated PCD: 2024-05-01
Drug
ribociclibProduct
BicalutamideClinical trial
Phase II Study of the Combination of Liposomal Irinotecan (Nal-IRI) and Pembrolizumab for Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)Status: Withdrawn, Estimated PCD: 2027-01-31
Clinical trial
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in Triple-negative Metastatic Breast Cancer PatientsStatus: Recruiting, Estimated PCD: 2023-12-01
Drug
AbraxaneClinical trial
Clinical Trial of Autologous cMet Redirected T Cells Administered Intratumorally in Patients With Breast CancerStatus: Completed, Estimated PCD: 2018-08-13
Product
cMet RNA CAR T cellsClinical trial
Identification of Predictive Biomarkers of Response to Chemotherapy and Immune Checkpoint Inhibitors in Early Triple Negative Breast Cancer: an Integrative Multiomics PlatformStatus: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or LymphomasStatus: Recruiting, Estimated PCD: 2025-04-01
Product
IMT-009Clinical trial
Phase II Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2022-05-01
Clinical trial
Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2024-03-31
Clinical trial
Neoadjuvant Fluzoparib Combined With Chemotherapy in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer: an Open, Multicenter, Cohort TrialStatus: Recruiting, Estimated PCD: 2025-06-01
Product
Fluzoparib+PaclitaxelProduct
Epirubicin+CyclophosphamideClinical trial
Phase Ib Clinical Trial of Autologous Anti-NY-ESO-1 TCR-Engineered T Cells in Patients With Relapsed/Refractory Locally Advanced or Metastatic NY-ESO-1-Expressing Triple Negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-08-01
Drug
interleukin-2Clinical trial
Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase 1, Open-Label, Dose-Escalation and Expansion Study of AGX101, a TM4SF1 Directed Antibody Drug Conjugate in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors Including Triple-Negative Breast Cancer and Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-05-01
Product
AGX101Clinical trial
A Phase 2a, Single-arm, Multi-center, Open-label Study of Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC PatientsStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Product
INBRX-106Clinical trial
A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2025-02-01
Product
Taxane BClinical trial
Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2020-09-02
Drug
CelecoxibDrug
RintatolimodClinical trial
HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid TumoursStatus: Recruiting, Estimated PCD: 2026-09-01
Product
HMBD-001Clinical trial
Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast CancerStatus: Not yet recruiting, Estimated PCD: 2024-06-30
Product
ImatinibClinical trial
Prospective Phase II Pilot Study, Assessing Imaging Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT (Positron Emission Tomography/Computerized Tomography) in Metastatic Triple Negative Breast Cancer PatientsStatus: Recruiting, Estimated PCD: 2024-03-01
Product
89Zr-TLX250Clinical trial
Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)Status: Recruiting, Estimated PCD: 2024-06-01
Product
HER3Clinical trial
A Pre-Surgical Window of Opportunity Trial Investigating the Effect of Cyclosporin A on Triple Negative Breast Cancer With Defective DNA RepairStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Product
Cyclosporin AClinical trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib TrialStatus: Withdrawn, Estimated PCD: 2021-11-17
Product
Vic-trastuzumab duocarmazineClinical trial
A Phase 1b Followed by Phase II Expansion Trial of Combination of Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer (ComPACT)Status: Recruiting, Estimated PCD: 2025-12-31
Product
Pembrolizumab & ADG106Clinical trial
A Randomized, Open-label Phase III Clinical Trial Comparing Antivascular Therapy Combined With Standard Chemotherapy and Standard Chemotherapy in Adjuvant Therapy for Patients With Triple-Negative Breast Cancer, Basal-like Immunosuppressed Subtype (BCTOP-T-A03)Status: Recruiting, Estimated PCD: 2029-05-30
Product
Antivascular therapyClinical trial
Phase II Clinical Trial to Evaluate the Efficacy and Safety of First Line Atezolizumab in Combination With Paclitaxel and Bevacizumab (Avastin®) in Patients With Advanced or Metastatic Triple-negative Breast CancerStatus: Completed, Estimated PCD: 2023-12-07
Clinical trial
Phase I Trial of Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Patients With Non-Metastatic Triple-Negative Breast Cancer at High Risk of RecurrenceStatus: Recruiting, Estimated PCD: 2024-11-01
Product
α-lactalbuminProduct
ZymosanClinical trial
PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Breast or Lung CancerStatus: Recruiting, Estimated PCD: 2025-01-01
Product
Systemic TherapyClinical trial
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-09-01
Product
Atezolizumab + BDB001 + RTProduct
Atezolizumab + BDB001Clinical trial
A Randomised, Open-label Phase II Study to Determine the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in Women With Triple-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2021-01-29
Product
TirelizumabProduct
DalpiciclibDrug
SHR-A1811Clinical trial
Does Cryoablation Boost Immune Response Improving the Benefits of Pembrolizumab in Patients With Metastatic or Locally Advanced Triple Negative Breast Cancer?Status: Recruiting, Estimated PCD: 2027-01-29
Clinical trial
Phase II Trial of Circulating Tumor DNA Monitoring During Adjuvant Capecitabine in Patients With Triple-negative Breast Cancer and Residual Disease Following Standard Neoadjuvant ChemotherapyStatus: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-10-01
Product
PRO1184Drug
R-CHOPClinical trial
Precision DC: Personalized Neoantigen Dendritic Cell Vaccine Pilot Trial for High Risk Triple Negative Breast Cancer After Neoadjuvant TherapyStatus: Recruiting, Estimated PCD: 2029-05-01
Product
Dendritic Cell VaccineClinical trial
4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast CancerStatus: Recruiting, Estimated PCD: 2024-07-01
Product
Seviteronel-DClinical trial
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or PlaceboStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
VarlilumabClinical trial
Efficacy and Safety Study of TA(E)C-GP Versus A(E)C-T for the High Risk Triple-negative Breast Cancer Patients Predicted by the Messenger RNA (mRNA)-Long Non-coding RNA (lncRNA) Signature and Validation of the Signature's EfficacyStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Drug
docetaxelProduct
Doxorubicin or EpirubicinProduct
gemcitabineProduct
cisplatinClinical trial
A Phase I/II Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersStatus: Recruiting, Estimated PCD: 2027-12-30
Product
HBI 0201-ESO TCRTClinical trial
A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2027-04-01
Product
APL-5125Clinical trial
Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Pembrolizumab in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-01
Product
ZM008Clinical trial
ALICE: A Randomized Placebo-controlled Phase II Study Evaluating Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast CancerStatus: Completed, Estimated PCD: 2023-04-25
Product
ALX148Product
Fam-Trastuzumab DeruxtecanClinical trial
Local Therapy Optimization by Grouping Immune-modulation With Cryoablation (LOGIC) for High Risk Breast CancersStatus: Not yet recruiting, Estimated PCD: 2027-01-01
Clinical trial
BRE-01: Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel Followed by Doxorubicin and Cyclophosphamide in Triple Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2026-09-27
Clinical trial
A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2022-11-30
Clinical trial
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer With and Without Intra-operative RT: a Window of Opportunity StudyStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Phase II Clinical Trial of Treatment With TAK-228 and TAK-117 to Inhibit Homologous Recombination (HR) Followed by Cisplatin and Nab Paclitaxel in Patients With Chemotherapy-pretreated Metastatic Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2020-03-17
Product
Tak-228Product
Cisplatin + Nab PaclitaxelClinical trial
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor IndicationsStatus: Recruiting, Estimated PCD: 2026-07-01
Drug
ABBV-400Clinical trial
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified CutoffStatus: Recruiting, Estimated PCD: 2025-09-30
Drug
SpartalizumabClinical trial
Targeting Triple-negative Breast Cancer or ER-positive, PR Positive her2 Negative by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2024-12-31
Product
Alkaline GlucosodieneClinical trial
A Molecular Pathway-based Umbrella Trial for First-line Precision Therapy With TROP2 in Patients With Locally Advanced or Metastatic TNBC (Future-Trop2 Study)Status: Not yet recruiting, Estimated PCD: 2024-03-01
Product
A1:SGProduct
A2:SGProduct
B1:SGProduct
B2:SGProduct
C1:SGProduct
C2:SGProduct
D1:SG with VEGFRIProduct
D2:SGClinical trial
A Phase I Trial of the Combination of Olaparib and Navitoclax in Women With High Grade Serous Epithelial Ovarian Cancer and Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-04-28
Product
NavitoclaxClinical trial
A Non-randomized, Non-comparative, Open-label, Window Trial of Entinostat Given With or Without Exemestane in Patients With Newly Diagnosed, Stage I-IIIC, Hormone Receptor - Positive (HR+) or Triple Negative Breast Cancer (TNBC)Status: Terminated, Estimated PCD: 2019-09-18
Product
EntinostatClinical trial
A Single-arm, Prospective Phase II Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid TumoursStatus: Recruiting, Estimated PCD: 2024-08-01
Product
FosifloxuridineClinical trial
Monitoring Breast Cancer Immunotherapy Treatment With Advanced PET/MRI: A Pilot StudyStatus: Not yet recruiting, Estimated PCD: 2026-08-02
Product
BNT327Product
Taxane AProduct
Alkylating agentProduct
AntimetaboliteClinical trial
ASTEROID:A Phase I Trial of ASTX660 in Combination With Pembrolizumab in Patients With Solid Tumours: Utilizing Triple IAP Blockade as a Strategy to Maximize Immunogenic Cell Death and the Generation of an Efficient Adaptive Immune ResponseStatus: Recruiting, Estimated PCD: 2026-03-16
Product
ASTX660Clinical trial
Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIAStatus: Recruiting, Estimated PCD: 2027-03-30
Clinical trial
BRE-03: Window of Opportunity Trial of Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)Status: Recruiting, Estimated PCD: 2026-12-01
Product
L-NMMAProduct
HER2-primed Dendritic cellsClinical trial
Pilot Feasibility Study: Inflammation and Presence of M2 Macrophages Explorations With[18F]-DPA-714 PET/CT in Triple Negative Breast CancersStatus: Completed, Estimated PCD: 2021-07-21
Product
[18F]-DPA-714 PET/CT scanClinical trial
A Phase II Study of Neoadjuvant Carboplatin/Paclitaxel Followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients With Hormone Receptor Negative, HER2 Receptor Negative Breast CancerStatus: Completed, Estimated PCD: 2020-03-23
Drug
FilgrastimClinical trial
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer With BRCA1, BRCA2, PALB2, RAD51C or RAD51D Mutations or RAD51-foci Low Test: RADIOLA TRIALStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination With Pembrolizumab in Selected Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-12-01
Product
XmAb®808Product
KeytrudaClinical trial
Neoadjuvant Anthracycline Followed by Toripalimab Combined With Nab-paclitaxel in Patients With Early Triple-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2022-09-28
Product
EpirubicinProduct
Albumin bound paclitaxelClinical trial
Immunogenicity Profile of Neoadjuvant Keytruda in Combination With Anthracycline Versus Carboplatin/PAclitaxel Containing Chemotherapy Regimen for The Treatment of Early-stage, TILs-Positive, Triple-Negative Breast CanceRStatus: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an Anti- αvβ3 Integrin Cytotoxin, in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Product
ProAgioClinical trial
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2027-05-01
Product
LY4052031